ID
22828
Description
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 23: Visit 4 (Week 7) PRN Subject Diary Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862
Link
https://clinicaltrials.gov/ct2/show/NCT00225862
Keywords
Versions (2)
- 6/8/17 6/8/17 -
- 6/12/17 6/12/17 -
Uploaded on
June 12, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 23: Visit 4 (Week 7) PRN Subject Diary
Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 23: Visit 4 (Week 7) PRN Subject Diary
Description
RLS episode
Alias
- UMLS CUI-1
- C0035258
- UMLS CUI-2
- C0332189
Similar models
Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 23: Visit 4 (Week 7) PRN Subject Diary
C1955348 (UMLS CUI-2)
C0035258 (UMLS CUI-3)
C0035258 (UMLS CUI [1,2])
C0332189 (UMLS CUI [1,3])
C0035258 (UMLS CUI [1,2])
C0332189 (UMLS CUI [1,3])